Table 4.

Multivariate analysis for significant baseline biomarkers for (a) progression-free and (b) overall survival in 96 mCRPC-patients prior to Abiraterone therapy and (c) progression-free survival and (d) overall survival in 17 patients with a baseline NLR >5 after eight weeks of therapy.

(a) Multivariate Analysis PFS at Baseline			(c) Multivariate analysis of PFS in n =17 Patients with Baseline NLR >5 after Eight Weeks of Abiraterone
Variable	HR (95%CI)	p	Variable	HR (95%CI)	p
ECOG		0.01	NLR		0.11
0–1	1 (reference)		No change	1 (reference)
2	2.6 (1.5–4.5)		Change to <5	3.4 (0.8–15.2)
LDH baseline >UNL		0.01	PSA decline ≥50%		0.14
No	1 (reference)		Yes	1 (reference)
Yes	2.2 (1.3–3.8)		No	1.5 (0.3–6.4)
Visceral metastases		0.04
No	1 (reference)
Yes	1.7 (1.0–2.9)
ALP baseline >UNL		0.25
No	1 (reference)
Yes	1.3 (0.8–2.1)
NLR		0.71
<5	1 (reference)
>5	1.1 (0.6–2.0)
(b) Multivariate analysis OS at baseline			(d) Multivariate Analysis of OS in n = 17 Patients with Baseline NLR >5 after Eight Weeks of Abiraterone
Variable	HR (95%CI)	p	Variable	HR (95%CI)	p
ECOG		<0.01	NLR		0.47
0–1	1 (reference)		No change	1 (reference)
2	3.0 (1.6–5.5)		Change to <5	1.6 (0.5–5.6)
LDH baseline >UNL		0.01	PSA decline ≥50%		0.25
No	1 (reference)		Yes	1 (reference)
Yes	2.4 (1.2–4.6)		No	2.2 (0.6–8.1)
Visceral metastases		0.56
No	1 (reference)
Yes	1.2 (0.7–2.1)
ALP baseline >UNL		0.05
No	1 (reference)
Yes	1.7 (1.0–2.9)
NLR		0.10
<5	1 (reference)
>5	1.7 (0.9–3.0)

Abbreviations: PFS: progression free survival; HR: hazard ratio; 95%CI: 95% confidence interval; ECOG: Eastern Collaborative Oncology Group; LDH: lactate dehydrogenase; UNL: upper normal limit; PSA: prostate-specific antigen; NLR: neutrophil-to-lymphocyte ratio; ALP: alkaline phosphatase; OS: overall survival.